Some PIs have greater impact than others on heart disease. Patients on atazanavir had less heart problems.
Recent research has highlighted the cardiovascular problems that some HIV patients have had while being treated with protease inhibitors (PIs), but it's been difficult for physicians to determine exactly which drugs are causing the most trouble. Now a new study, presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held Dec. 16-19, 2005, in Washington, DC, shows that there is a significant difference in coronary risk depending on which PI a patient takes. Investigators found that patients receiving atazanavir had a significantly lower risk over a 10-year period of coronary heart disease than did patients receiving nelfinavir, and this lower risk remained statistically significant for patients who had other heart disease risk factors, including smoking, diabetes, and hypertension.
D000069446:Atazanavir Sulfate; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006331:Heart Diseases / Q000139:chemically induced*; D006801:Humans; D009842:Oligopeptides / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*
D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate